# US 6,727,260 B2 · Inhibitors of proton-gated cation channels and their use in the treatment of ischaemic disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,727,260 B2
- Document ID: US6727260B2
- Status: Granted
- Kind: B2
- Application number: 09/985,887
- Filed: 2001-11-06
- Published: 2002-05-16
- Granted: 2004-04-27
- Earliest claimed: 1999-05-19
- Assignees: NeuroSearch A/S
- Inventors: Thomas Varming; Frank Wätjen
- Web page: https://patentgrep.com/patent/US6727260B2

## CPC

- A61K 31/47: Quinolines; Isoquinolines
- A61K 31/4745: condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines (yohimbine derivatives, vinblastine A61K31/475; ergoline derivatives A61K31/48)
- A61K 31/498: Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This invention relates to the use of compounds capable of inhibiting the activity of a proton-gated cation channel in the treatment of alleviation of diseases or disorders associated with, or mediated by a drop in extra cellular pH.

## Claims

### Claim 1

A method of inhibiting a mammalian proton-gated ion channel with an isatin derivative represented by the general Formula I
or a pharmaceutically acceptable salt thereof, wherein
R1 represents hydrogen, alkyl, phenyl or benzyl; and
X represents oxygen, or a group of the formula NOR2, wherein R2 represents hydrogen, alkyl, acyl, phenyl, or benzyl; and
Y represents a group of the formula N—R4, wherein R4 represents hydrogen, hydroxy or alkyl; and
n is 0; and
R6 represents phenyl, naphthyl, thienyl, or pyridyl all of which groups may be substituted one or more times with halogen, CF3, nitro, amino, cyano, hydroxy, alkyl, alkoxy, phenyl, or a group of the formula —SO2NR′R″, wherein R′ and R″ independently of each other represents hydrogen or alkyl; and
“A” represents ring holding of six atoms, which ring is fused to the benzo-ring at the positions marked “a” and “b”, and formed by one or the following bivalent radicals:
(a) —NR12—CH2—CH2—CH2— (b),
(a) —CH2—NR2—CH2—CH2— (b),
(a) —CH2—CH2—NR12—CH2— (b),
(a) —CH2—CH2—CH2—NR12 — (b),
wherein
R12 represents hydrogen, alkyl, alkyl substituted with hydoxy, alkoxy-alkyl, alkoxy-carbonyl-alkyl, alkyl-carbonyl-oxy-alkyl, cycloalkyl, cycloalkyl-alkyl, alkenyl, alkynyl, phenyl or benzyl, which phenyl or benzyl group is optionally substituted with halogen, CF3, nitro, amino, cyano, hydroxy-alkyl, alkoxy, or a group of the formula —SO2NR′R″, wherein R′ and R″ independently of each other represents hydrogen or alkyl.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the compound is represented by the general Formula II
or a pharmaceutically acceptable salt thereof,
wherein R1, R6, R12, X, Y and n have the meanings set forth in claim 1.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the compound is represented by the general Formula III
or a pharmaceutically acceptable salt thereof,
wherein R1, R6, R12 and X have the meanings set forth in claim 1.

### Claim 4 (depends on 3)

The method according to claim 3, wherein the compound is
8-ethyl-5-phenyl-6-7-8-9-tetrahydro-1H-pyrrolo- [3,2-h]-isoquinoline-2,3-dione-3-oxim;
8-methyl-5-phenyl-6-7-8-9-tetrahydro-1H-pyrrolo- [3,2-h]-isoquinoline-2,3-dione-3-oxim;
8-methyl-5-(4-nitrophenyl)-6,7,8,9-tetrahydro-1H-pyrrolo-[3,2-h]-isoquinoline-2,3-dione-3-oxim;
8-methyl-5-phenyl-6-7-8-9-tetrahydro-1H-pyrrolo-[3,2-h]-isoquinoline-2,3-dione-3-methyloxim;
5-phenyl-6-7-8-9-tetrahydro-1H-pyrrolo-[3,2-h]-isoquinoline-2,3-dione-3-oxim;
8-ethyl-5-phenyl-6-7-8-9-tetrahydro-1-methyl-pyrrolo-[3,2-h]-isoquinoline-2,3-dione-3-oxim;
8-methyl-5-(4-fluorophenyl)-6,7,8,9-tetrahydro-1H-pyrrolo-[3,2-h]-isoquinoline-2,3-dione-3-oxim;
5-(4-chlorophenyl)-8-methyl-6-7-8-9-tetrahydro-1-H-pyrrolo-[3,2-h]-isoquinoline-2,3-dione-3-oxim;
5-(2-naphthyl)-8-methyl-6-7-8-9-tetrahydro-1-H-pyrrolo-[3,2-h]-isoquinoline-2,3-dione-3-oxim;
8-methyl-5-phenyl-6,7,8,9-tetrahydro-1H-pyrrolo-[3,2-h]-isoquinoline-2,3-dione-3-acetyloxim;
8-methyl-5-(4-(N,N-dimethylsulfamoyl)-phenyl)-6,7,8,9-tetrahydro-1H-pyrrolo-[3,2-h]-isoquinoline-2,3-dione-3-oxime;
8-methyl-5-(4-toluyl)-6-7-8-9-tetrahydro-1-H-pyrrolo-[3,2-h]-isoquinoline-2,3-dione-3-oxim;
8-methyl-5-(4-methoxyphenyl)-6-7-8-9-tetrahydro-1-H-pyrrolo-[3,2-h]-isoquinoline-2,3-dione-3-oxim;
8-methyl-5-(3-methoxyphenyl)-6-7-8-9-tetrahydro-1-H-pyrrolo-[3,2-h]-isoquinoline-2,3-dione-3-oxim;
8-methyl-5-phenyl-6-7-8-9-tetrahydro-1-H-pyrrolo-[3,2-h]-isoquinoline-2,3-dione-3-O-2,2-dimethylpropanoyl-oxim;
8-methyl-5-(2-methoxyphenyl)-6-7-8-9-tetrahydro-1-H-pyrrolo-[3,2-h]-isoquinoline-2,3-dione-3-oxim;
8-benzyl-5-phenyl-6-7-8-9-tetrahydro-1H-pyrrolo-[3,2-h]-isoquinoline-2,3-dione-3-oxim;
8-methoxycarbonylmethyl-5-phenyl-6,7,8,9-tetrahydro-1H-pyrrolo-[3,2-h]-isoquinoline-2,3-dione-3-oxime;
8-(2-propynyl)-5-phenyl-6,7,8,9-tetrahydro-1H-pyrrolo-[3,2-h]-isoquinoline-2,3-dione-3-oxime; or
8-cyclopropylmethyl-5-phenyl-6,7,8,9-tetrahydro-1H-pyrrolo-[3,2-h]-isoquinoline-2,3-dione-3-oxime;
8-ethyl-5-phenyl-6-7-8-9-tetrahydro-1-methyl-pyrrolo [3,2-h]-isoquinoline-2,3-dione-3-oxim;
8-ethyl-5-phenyl-6-7-8-9-tetrahydro-1-methyl-pyrrolo-[3,2-h]-isoquinoline-2,3-dione-3-O -methyloxim;
or a pharmaceutically acceptable salt thereof.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the compound is represented by the general Formula IV
or a pharmaceutically acceptable salt thereof,
wherein R1, R6, R12, X, Y and n have the meanings set forth in claim 1.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the compound is represented by the general Formula V
or a pharmaceutically acceptable salt thereof,
wherein R1, R6, R12 and X have the meanings set forth in claim 1.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the compound is represented by the general Formula VI
or a pharmaceutically acceptable salt thereof,
wherein R1, R6, R12, X, Y and n have the meanings set forth in claim 1.

### Claim 8 (depends on 1)

The method according to claim 1, wherein the compound is represented by the general Formula VII
or a pharmaceutically acceptable salt thereof,
wherein R1, R6, R12 and X have the meanings set forth in claim 1.

### Claim 9 (depends on 8)

The method according to claim 8, wherein the compound is
7-ethyl-5--phenyl-6,7,8,9-tetrahydro-1H-pyrrolo-[3,2-f]-isoquinoline-2,3-dione-3-oxim; or
5-phenyl-7-methyl-6-7-8-9-tetrahydro-1-methyl-pyrrolo-[3,2-f]-isoquinoline-2,3-dione-3-oxim;
or a pharmaceutically acceptable salt thereof.

### Claim 10

A method for the treatment, prevention or alleviation of a disease, disorder or condition in a subject, which disease, disorder or condition is associated with, or mediated by a drop in extracellular pH, which comprises inhibiting cation channels by administering to the subject a pharmaceutically effective amount of an isatin derivative represented by the general Formula I
or a pharmaceutically acceptable salt thereof, wherein
R1 represents hydrogen, alkyl, phenyl or benzyl; and
X represents oxygen, or a group of the formula NOR2, wherein R2 represents hydrogen, alkyl, acyl, phenyl, or benzyl; and
Y represents a group of the formula N—R4, wherein R4 represents hydrogen, hydroxy or alkyl; and
n is 0; and
R6 represents phenyl, naphthyl, thienyl, or pyridyl all of which groups may be substituted one or more times with halogen, CF3, nitro, amino, cyano, hydroxy, alkyl, alkoxy, phenyl, or a group of the formula —SO2NR′R″, wherein R′and R″ independently of each other represents hydrogen or alkyl; and
“A” represents ring holding of six atoms, which ring is fused to the benzo-ring at the positions marked “a” and “b”, and formed by one or the following bivalent radicals:
(a) —NR12—CH2—CH2—CH2— (b),
(a) —CH2—NR12—CH2—CH2— (b),
(a) —CH2—CH2—NR2—CH2— (b),
(a) —CH2—CH2—CH2—NR12— (b),
wherein
R12 represents hydrogen, alkyl, alkyl substituted with hydoxy, alkoxy-alkyl, alkoxy-carbonyl-alkyl, alkyl-carbonyl-oxy-alkyl, cycloalkyl, cycloalkyl-alkyl, alkenyl, alkynyl, phenyl or benzyl, which phenyl or benzyl group is optionally substituted with halogen, CF3, nitro, amino, cyano, hydroxy-alkyl, alkoxy, or a group of the formula —SO2NR′R″, wherein R′ and R″ independently of each other represents hydrogen or alkyl.

### Claim 11 (depends on 10)

The method according to claim 10, in which the disease or disorder is a diseases associated with reduced blood flow to the brain and other CNS tissue, or associated with instances of a temporary break in blood supply to the brain or to other CNS tissue.

### Claim 12 (depends on 10)

The method according to claim 10, in which the disease or disorder is an ischaemic disease, an anoxic episode, an injury to the brain and other parts of the CNS caused by trauma or other injury, a blow to the head, or a spinal injury, a tromboembolic or haemorrhagic stroke, a cerebral vasospasm, hypoglycaemia, cardiac arrest, status epilepticus, perinatal asphyxia, anoxia, cerebral trauma, lathyrism, Alzheimer's disease, and Huntington's disease, cerebral ischaemia or cerebral infarction, ischaemic, hypoxic or anoxic brain damage, spinal cord injury, tissue ischaemia and reperfusion injury in a mammal at risk for such damage.

### Claim 13 (depends on 10, 11, 12)

The method according to any of claims 10-12, in which the isatin derivative is an ASIC1-, ASIC1A-, ASIC1B-, ASIC2-, ASIC2A-, ASIC2B-, ASIC3-, or ASTC-β- inhibiting compound.

### Claim 14 (depends on 13)

The method according to claim 13, which method further comprises rises simultaneous administration of the isatin derivative and a pharmaceutically effective amount of an AMPA receptor antagonist.

### Claim 15 (depends on 14)

The method according to claim 14, wherein the AMPA receptor antagonising compound is
2,3-dihydroxy-6-nitro-7-sulphamoyl-benzo-(f)-quinoxaline (NBQX);
6,7-dinitroquinoxaline-2,3-dione; or
6-cyano-7-nitroquinoxaline-2,3-dione;
or a pharmaceutically acceptable salt thereof.

### Claim 16 (depends on 10)

The method of claim 10, wherein the subject is a human being.
